


Amendments to the Specification:


Please delete the first paragraph of page 5, lines 11-15 and the chemical structure that follows:

~~Kundu and collaborators have described benzamides (3), (4) and (5) as N - α -glucosidase inhibitors (*Comb. Chem. High.* **2002**, 5, 545-550). These compounds are structurally close to those of this invention, but were described for different uses.~~



Please replace the last paragraph of page 5, with following amended paragraph:

Kundu and collaborators have described benzamides (3), (4) and (5) as N - α -glucosidase inhibitors (*Comb. Chem. High.* **2002**, 5, 545-550). WO 02/096426 discloses compounds (6) and (7) as intermediates for compounds which are matrix metalloproteinase inhibitors. Finally, WO 04/014844 discloses compounds (8) and (9) as factor IX modulators. These compounds are structurally close to those of this invention, but were described for different uses.



	<u>R</u>	<u>R'</u>	<u>R''</u>
(3)	Phenyl-	Benzyl-	-H
(4)	4-Methoxyphenyl-	Benzyl-	-H
(5)	4-Bromophenyl-	Benzyl-	-H
(6)	2-Methylquinolin-4-yl-	Cyclopentyl-	-methyl
(7)	2-Methylquinolin-4-yl-	Tetrahydropyran-4-yl-	-methyl
(8)	Phenyl-	Biphenyl-4-ylmethyl	-H
(9)	Phenyl-	4'-Trifluoromethoxybiphenyl- 4-methyl-	-H

Please replace the first paragraph of page 66, lines 1-3, with following amended paragraph:

The compounds of formula (Ia) shown in Table 15 were synthesized according to methods N or P, starting from compounds of formula (Ib).

Please replace TABLE 19 that appears at pages 89-90, with following amended TABLE 19:

TABLE 19

Ex.	Affinity PPAR γ ⁽¹⁾	Functional activity PPAR γ	Affinity PPAR[[γ]] $\underline{\alpha}$ ⁽¹⁾	Affinity PPAR[[γ]] $\underline{\delta}$ ⁽¹⁾
20	+++	Partial agonist	+	+
21	+++	Partial agonist	+	+
27	+++	Antagonist	+	+
95	+++	Agonist	+	+
98	+++	Antagonist	+	+
129	+++	Partial agonist	+	+
131	++	Partial agonist	+	+

Ex.	Affinity PPAR γ ⁽¹⁾	Functional activity PPAR γ	Affinity PPAR[[γ]] $\underline{\alpha}$ ⁽¹⁾	Affinity PPAR[[γ]] $\underline{\delta}$ ⁽¹⁾
136	++	Antagonist	+	++
141	++	Antagonist	+	++
142	++	Antagonist	+	++
145	++	Antagonist	+	+
146	++	Antagonist	+	+
153	++	Partial agonist	+	+
160	+	Partial agonist	+	+
161	++	Antagonist	+	+
162	+++	Antagonist	+	+
163	+++	Antagonist	+	+
164	++	Antagonist	+	+
170	++	Antagonist	+	+
176	+++	Antagonist	++	+
180	+++	Partial agonist	++	+
183	+++	Partial agonist	+	+
184	+++	Antagonist	+	-
185	+++	Partial agonist	+	+
187	+++	Agonist	+	+
188	+++	Partial agonist	+	+
192	+	Partial agonist	+	+
210	+++	Agonist	+	+
218	+++	Antagonist	+	+
237	+++	Partial agonist	+	+
238	+++	Antagonist	+	+
243	+++	Antagonist	+	+
267	++	Partial agonist	+	-1

⁽¹⁾ +++ : Ki < 1000 nM, ++: 1000 nM < Ki < 3000 nM, + : Ki > 3000 nM